Login / Signup
(Updated) –Oral anticoagulant reduced CV events in patients with coronary and peripheral disease. The very large COMPASS study has been stopped early for “overwhelming efficacy,”…
Eliquis Nipping At The Heels of NOAC Market Leader Xarelto
–But the overall market for the new oral anticoagulants continues to expand. The new oral anticoagulant (NOAC) market is growing larger and is becoming increasingly…
More Bleeding Linked To Rivaroxaban In Observational Study
–Compared to dabigatran, rivaroxaban was associated with more intracranial and other serious bleeds. A new observational study finds that patients who take rivaroxaban (Xarelto, Johnson…
Reality Check: After Starting Warfarin One In Five Older Vets Hospitalized For Bleeding
A new study presented at the American Heart Association meeting in Orlando finds that more than one in five elderly US veterans are hospitalized for bleeding…